In a research note, UBS analyst Michael Leuchten has maintained his recommendation on the stock with a Neutral rating. The target price remains set at GBX 12500. | June 5, 2023
AstraZeneca and Daiichi Sankyo’s ENHERTU showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 Phase II trial
ENHERTU is the first therapy to show. | June 5, 2023
In his latest research note, analyst Emily Field confirms his positive recommendation. The broker Barclays is keeping its Buy rating. The target price is unchanged and still at GBX 13500. | June 5, 2023
By Elena Vardon AstraZeneca said Monday that the phase II trial for its cancer drug Enhertu showed clinically meaningful and durable responses across patients with HER2-expressing advanced. | June 5, 2023
AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday reported positive results from trials of two cancer drugs, Enhertu and datopotamab deruxtecan.
AstraZeneca and Daiichi Sankyo are global. | June 5, 2023